Roche Holding AG (LON:0QQ6)
331.20
+4.69 (1.44%)
At close: Dec 19, 2025
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
4.49
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
261.47B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Roche Holding AG News
- 9 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 9 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 9 days ago - Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease - Benzinga
- 9 days ago - Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III - Nasdaq
- 10 days ago - Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack - Nasdaq
- 10 days ago - Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu - GlobeNewsWire
- 10 days ago - Questex's Patients as Partners® in Clinical Research Unveils Conference Program, Thought Leaders from Lurie Children's Hospital, Roche Canada and Tufts University School of Medicine to Keynote - GlobeNewsWire
- 10 days ago - Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus